Download PDF
Klin Padiatr 2015; 227(06/07): 308-313
DOI: 10.1055/s-0035-1555792
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Die Hypereosinophilie-Syndrome (HES) im Kindesalter

The Hypereosinophilic Syndromes in Childhood
T. Leu
1   Universitäts-Kinderklinik Würzburg, Würzburg
3   Kinderklinik, Klinikum Nürnberg-Süd, Nürnberg
,
H.-U. Simon
2   Institut für Pharmakologie, Universität Bern, Bern
,
H. Hebestreit
1   Universitäts-Kinderklinik Würzburg, Würzburg
,
S. Kunzmann
1   Universitäts-Kinderklinik Würzburg, Würzburg
› Author Affiliations
Further Information

Publication History

Publication Date:
12 August 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Hypereosinophilie-Syndrome (HES) sind in der Pädiatrie nur selten anzutreffende Erkrankungen und erfordern umfangreiche differenzialdiagnostische Überlegungen. In den letzten Jahren konnte das früher als „idiopathische HES“ bezeichnete Krankheitsbild mehr und mehr in molekularbiologisch, immunphänotypisch und klinisch näher charakterisierte heterogene Krankheitsbilder mit hoher therapeutischer und prognostischer Relevanz differenziert werden. Unter dem Begriff HES werden heute Erkrankungen zusammengefasst, die mit einer systemischen oder lokalen Hypereosinophilie (HE) und einer damit verbunden Schädigung der Organe einhergehen. In Abhängigkeit von der Ursache unterscheidet man primär-neoplastische HES (HESN) und sekundär/reaktive HES (HESR). Letztere entstehen reaktiv u. a. in Zusammenhang mit einer klonalen Vermehrung von T-Lymphozyten, Allergien, Parasitosen, Medikamenteneinnahmen oder Neoplasien. Bei HESN entsteht die HE durch eine klonale Vermehrung der Eosinophilen. Während für einige Subgruppen der HESN (u. a. FIP1L1-PDGFRA-Fusionsgen) die Gabe von Tyrosinkinase-Inhibitoren eine neue und effektive Therapieoption darstellt, sind Glukokortikoide weiterhin für viele nicht PDGFRA assoziierte Varianten das Präparat der ersten Wahl. Zur oftmals nötigen Dosiseinsparung der Glukokortikoide kommen verschiedene immunmodulatorische oder zytostatische Medikamente zum Einsatz. Die vielversprechende Therapie mit Anti-IL-5 Antikörpern besitzt derzeit (noch) keine Zulassung im Kindesalter, könnte aber für die Zukunft eine Behandlungsoption werden. Aufgrund des derzeitigen Mangels an Wissen über die HES im Kindesalter sollte die Einrichtung eines Registers zur Behandlung der HES im Kindesalter angestrebt werden.

Abstract

The hypereosinophilic syndromes are rare disorders in childhood and require extensive differential diagnostic considerations. In the last years the earlier “idiopathic HES” called syndromes could be differentiated into molecular biologically, immunophenotypically and clinically more characterized heterogeneous diseases with high therapeutic and prognostic relevance. Nowadays the term HES summarizes diseases, which go hand in hand with a local or systemic hypereosinophilia (HE) connected with an organ damage. Depending on the cause of the HE one differentiates primary/neoplastic HES (HESN) from secondary/reactive HES (HESR). The latter develops reactively in connection with allergies, parasitosis, medications, neoplasia or a clonal increase of T-lymphocytes among others. With HESN the HE results from a clonal increase of eosinophilic granulocytes. While for some subgroups of the HESN (among others FIP1L1-PDGFRA fusion gene) the administration of a tyrosine kinase inhibitor is a new and effective therapy option, glucocorticoids still represent the medication of first choice for many not PDGFRA associated variants. Different immunomodulatory drugs or cytostatic agents are necessary to allow dose reduction of glucocorticoids. The promising therapy with anti-IL-5 antibodies is still not approved in infancy, could however become a treatment option in the future. Due to the present lack of knowledge about the HES in infancy the establishment of a register should be aimed for the treatment of HES in infancy.

Schlüsselwörter

eosinophile Alveolitis - Asthma bronchiale - Churg-Strauss-Syndrom - Imatinib - Mepolizumab

Key words

eosinophilic alveoltitis - asthma - churg-strauss-syndrome - imatinib - mepolizumab
 

  • Literatur

  • 1 Auer. Parasitosen . Pädiatrische Pneumologie. Springer-Verlag; 3. Auflage 528-535
    Google Scholar
  • 2 Camous X, Calbo S, Picard D et al. Drug Reaction with Eosinophilia and Systemic Symptoms: an update on pathogenesis. Current opinion in immunology 2012; 24: 730-735
    CrossrefPubMedGoogle Scholar
  • 3 Cools J, DeAngelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. The New England journal of medicine 2003; 348: 1201-1214
    CrossrefPubMedGoogle Scholar
  • 4 Cottin V, Cordier JF. Eosinophilic lung diseases. Immunology and allergy clinics of North America 2012; 32: 557-586
    CrossrefPubMedGoogle Scholar
  • 5 Ehrhardt S, Burchard GD. Eosinophilia in returning travelers and migrants. Deutsches Arzteblatt international 2008; 105: 801-807
    PubMedGoogle Scholar
  • 6 Farruggia P, Giugliano E, Russo D et al. FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome in childhood: a case report and review of literature. Journal of pediatric hematology/oncology 2014; 36: e28-e30
    CrossrefPubMedGoogle Scholar
  • 7 Freymond N, Kahn JE, Legrand F et al. Clonal expansion of T cells in patients with eosinophilic lung disease. Allergy 2011; 66: 1506-1508
    CrossrefPubMedGoogle Scholar
  • 8 Giovannini-Chami L, Hadchouel A, Nathan N et al. Idiopathic eosinophilic pneumonia in children: the French experience. Orphanet journal of rare diseases 2014; 9: 28
    CrossrefPubMedGoogle Scholar
  • 9 Gotlib J. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. American journal of hematology 2014; 89: 325-337
    CrossrefPubMedGoogle Scholar
  • 10 Gotlib J, Cools J, Malone 3rd JM et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103: 2879-2891
    CrossrefPubMedGoogle Scholar
  • 11 Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J et al. T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica 2009; 94: 1236-1241
    CrossrefPubMedGoogle Scholar
  • 12 Hellmich B, Holl-Ulrich K, Gross WL. Hypereosinophilic syndrome-recent developments in diagnosis and treatment. Deutsche medizinische Wochenschrift 2007; 132: 1892-1896
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Hellmich B, Holl-Ulrich K, Merz H et al. Hypereosinophilic syndrome and Churg-Strauss syndrome: is it clinically relevant to differentiate these syndromes?. Der Internist 2008; 49: 286-296
    CrossrefPubMedGoogle Scholar
  • 14 Kamisawa T, Zen Y, Pillai S et al. IgG4-related disease. Lancet 2014; DOI: 10.1016/S0140-6736(14)60720-0.
    PubMedGoogle Scholar
  • 15 Katz HT, Haque SJ, Hsieh FH. Pediatric hypereosinophilic syndrome (HES) differs from adult HES. The Journal of pediatrics 2005; 146: 134-136
    CrossrefPubMedGoogle Scholar
  • 16 Kaya H, Gumus S, Ucar E et al. Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia. Chest 2012; 142: 513-516
    CrossrefPubMedGoogle Scholar
  • 17 Klion AD, Bochner BS, Gleich GJ et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. The Journal of allergy and clinical immunology 2006; 117: 1292-1302
    CrossrefPubMedGoogle Scholar
  • 18 Löffler-Ragg JFR, Kähler ChM. Blood eosinophilia and associated lung diseases. J Pneumologie 2013; 1: 25-31
    PubMedGoogle Scholar
  • 19 Löffler W. Zur Differentialdiagnose der Lungeninfiltrierung – über flüchtige Infiltrate (mit Eosinophilie). Beitr Klin Tuberk 1932; 79: 368-392
    CrossrefPubMedGoogle Scholar
  • 20 Moosig F, Richardt G, Merten C et al. Hypereosinophilic syndrome. Der Internist 2013; 54: 426-433
    CrossrefPubMedGoogle Scholar
  • 21 Nagamura N, Ueno S, Fujishiro H et al. Hepatitis associated with hypereosinophilia suspected to be caused by HES that also presented with the pathological features of IgG4-related disease. Internal medicine 2014; 53: 145-149
    CrossrefPubMedGoogle Scholar
  • 22 Plotz SG, Simon HU, Darsow U et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. The New England journal of medicine 2003; 349: 2334-2339
    CrossrefPubMedGoogle Scholar
  • 23 Podjasek JC, Butterfield JH. Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature. Leukemia research 2013; 37: 392-395
    CrossrefPubMedGoogle Scholar
  • 24 Radonjic-Hoesli S, Valent P, Klion AD et al. Novel targeted therapies for eosinophil-associated diseases and allergy. Annual review of pharmacology and toxicology 2015; 55: 633-656
    PubMedGoogle Scholar
  • 25 Rapanotti MC, Caruso R, Ammatuna E et al. Molecular characterization of paediatric idiopathic hypereosinophilia. British journal of haematology 2010; 151: 440-446
    CrossrefPubMedGoogle Scholar
  • 26 Rothenberg ME, Klion AD, Roufosse FE et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. The New England journal of medicine 2008; 358: 1215-1228
    CrossrefPubMedGoogle Scholar
  • 27 Roufosse FE, Kahn JE, Gleich GJ et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. The Journal of allergy and clinical immunology 2013; 131: 461-467 e461-e465
    CrossrefPubMedGoogle Scholar
  • 28 Sade K, Mysels A, Levo Y et al. Eosinophilia: A study of 100 hospitalized patients. European journal of internal medicine 2007; 18: 196-201
    CrossrefPubMedGoogle Scholar
  • 29 Schreiber J. Drug-induced lung diseases. Deutsche medizinische Wochenschrift 2011; 136: 631-634
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Simon D, Simon HU. Eosinophilic disorders. The Journal of allergy and clinical immunology 2007; 119: 1291-1300
    CrossrefPubMedGoogle Scholar
  • 31 Simon HU, Plotz SG, Dummer R et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. The New England journal of medicine 1999; 341: 1112-1120
    CrossrefPubMedGoogle Scholar
  • 32 Simon HU, Plotz SG, Simon D et al. Clinical and immunological features of patients with interleukin-5-producing T cell clones and eosinophilia. International archives of allergy and immunology 2001; 124: 242-245
    CrossrefPubMedGoogle Scholar
  • 33 Simon HU, Rothenberg ME, Bochner BS et al. Refining the definition of hypereosinophilic syndrome. The Journal of allergy and clinical immunology 2010; 126: 45-49
    CrossrefPubMedGoogle Scholar
  • 34 Simon HU, Seger R. Hyper-IgE syndrome associated with an IL-4-producing gamma/delta(+) T-cell clone. The Journal of allergy and clinical immunology 2007; 119: 246-248
    CrossrefPubMedGoogle Scholar
  • 35 Valent P, Klion AD, Horny HP et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. The Journal of allergy and clinical immunology 2012; 130: 607-612 e609
    CrossrefPubMedGoogle Scholar
  • 36 van Grotel M, de Hoog M, de Krijger RR et al Hypereosinophilic syndrome in children. Leukemia research 2012; 36: 1249-1254
    CrossrefPubMedGoogle Scholar
  • 37 Zhang Q, Su HC. Hyperimmunoglobulin E syndromes in pediatrics. Current opinion in pediatrics 2011; 23: 653-658
    CrossrefPubMedGoogle Scholar